Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEP-3Na for Mild to Moderate Atopic Dermatitis
NCT04307862Phase 2Recruiting
- Sponsor
- Shulov Innovative Science
- Start
- Dec 2019
- Primary completion
- Dec 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ZEP-3 in atopic dermatitis (AD) (3 arms), sponsored by Shulov Innovative Science. Primary endpoint: Proportion of subjects with IGA 0 to 1 and reduction >= 2 points at 4 weeks. Started Dec 2019; status: recruiting.
02
Drugs
ZEP-3
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04307862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04307862.